Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Waker Biology

Request full access

Safety assessment services for cell and gene therapy

ChinaFounded 2021Biotech & Life Sciences

About Waker Biology

Waker Bioscience provides safety assessment services for cell and gene therapy drug products. The company specializes in insertion mutation risk assessment, quantitative off-target analysis for CRISPR/Cas9, and sgRNA screening. Their services cater to pharmaceutical clients, aiming to help them develop novel cell and gene therapies that meet regulatory safety standards. The service portfolio includes Integration Site Analysis, On-/Off-Target Analysis, Vector Copy Number, and Vector Quality Control.

Operating under GLP regulations, Waker Bioscience has an 800-square-meter laboratory and has established an advanced genomics and bioinformatics platform. The company's core technologies, S-EPTS/LM PCR and TES systems, originated from Manfred Schmidt's team at the German National Cancer Center. Waker Bioscience reports having participated in over 130 gene therapy projects globally and completed insertion mutation risk assessments for more than 50 clinical trials. They offer customized services that cover the entire process from sample receipt and quality control to library preparation, next-generation sequencing, bioinformatics analysis, and providing ISA risk assessment reports.

Source: Dealroom company data

At a glance

Status
Operational
Open positions
None listed
Dealroom signal
21.0/100
Industry
Health
Sub-industry
BioTechnology
Sector
Biotechnology, Drug Development, Biomarkers, Genetics and genomics, Crispr, Gene Therapy, Techbio, DT and LS, science-based
Business model
Manufacturing
Client focus
B2B
Links
Website

Funding history

2 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
SERIES A✓Equity / VC Nov 2025 $14M $55M Wuxi Innovation Investment Group · Shenzhen Capital Group ↗
ANGELEquity / VC Dec 2022 $0 — BGI Co-Win ↗
Showing the latest 2 of 2 recorded eventsBook a demo for the full funding history →

Growth signals

Waker Biology website traffic

Latest recorded traffic for Waker Biology is 1.1K monthly website visits, up 129.2% over the last three months.

Latest monthly visits1.1K 3-month web change+129.2%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Waker Biology in its local ecosystem

Live from Dealroom

The Waker Biology office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

3 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Seed1 investor entered at this stage

  • BGI Co-Win

Series A2 investors entered at this stage

Founders Hidden — book a demo/100 quality score
Key operators Hidden — book a demo quality score
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
🇨🇳 China HQ
Book a demo for the full country breakdown

See Waker Biology’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.